News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Oct 12, 2021Company Achieves Selective Reprogramming of Pathological Autoimmunity
(OTC-CELZ) Creative Medical Technology Holdings Inc. announced today proof of concept data demonstrating the ability of its next generation ImmCelz™ immunotherapy product to "reprogram" patient...
-
Oct 1, 2021
Creative Medical Technology Holdings Inc. (OTC – CELZ) announced today filing a new patent application covering nanoparticles called "exosomes" secreted by cells of its MyeloCelz™ platform and...
-
Sep 16, 2021
Creative Medical Technology Holdings, Inc. (OTC: CELZ), a commercial stage biotechnology company focused on a regenerative approach to Immunotherapy, Urology, Neurology and Orthopedics, today...
-
Aug 9, 2021
Creative Medical Technology Holdings, Inc. ("CELZ," the "Company", "we", "our" or "us") (OTC: CELZ) today announced that it has entered into definitive agreements with accredited institutional...
-
Jul 20, 2021Landmark Patent Containing Over 1000 Claims Filed
(OTC – CELZ) Creative Medical Technology Holdings Inc. announced today the launching of its second Regenerative Immunology product, MyeloCelz™. In contrast to the Company's ImmCelz™ product,...
-
Jun 22, 2021Courtney Bartlett DNP, ACNP-BC, RNFA to Lead Clinical Translation of Company's Regenerative Immunotherapy Pipeline
(OTC-CELZ) Creative Medical Technology Holdings announced today recruitment of Dr. Courtney Bartlett to lead clinical development of the Company's pipeline of therapeutic products. Dr. Bartlett...
-
Jun 17, 2021
Creative Medical Technology Holdings, Inc. (OTC - CELZ), announced that the company will virtually present at the Investor Forum at the World Stem Cell Summit today Thursday, June 17, 2021 at...
-
Jun 9, 2021Clinical Stage Regenerative Immunotherapy Company Optimizes Treatment for Diabetes as it Prepares for Additional Investigational New Drug Application
Creative Medical Technology Holdings, trading under Ticker Symbol CELZ, announced the filing of a provisional patent application in connection with new data indicating that the Company's ImmCelz®...
-
May 24, 2021Clinical Stage Biotechnology Company Reports Patent Filing based on Preclinical Data using "Regenerative Immunotherapy" Approach
Creative Medical Technology Holdings, trading under ticker symbol CELZ, announced today positive preclinical data supporting extension of ImmCelz® applicability to Parkinson's Disease. Using the...
-
May 20, 2021Immunologist Surgeon who Invented Islet Transplantation to Assist Company in Advancing ImmCelz® Platform
Creative Medical Technology Holdings announced today recruitment of Dr. Camillo Ricordi to the Company's Scientific Advisory Board. Dr. Ricordi will collaborate with Company Advisors such as Drs...